Erlotinib and Docetaxel in Second Line of Treatment in Patients With Non Small Cell Lung Cancer

Inclusion Criteria: * Histologically proven NSCLC ( * Mutational status of EGFR : wild type or unknown * Stage IV disease with cytologic or histologic documentation in patients with a single easily accessible metastasis or metastatic relapses in a non irradiated region from a primary tumor treated with surgery or radiotherapy (with cytologic or histologic documentation of relapse) * Presence of at least one measurable target lesion (one dimension) in a non irradiated region (at least 10 mm on spiral computed tomography). * Age ≥ 18 years * Performance status 0,1,2 exception : age \> 74 years only PS 0 or 1 * Normal hepatic function * Normal renal function * Normal calcemia * Normal haematological function * Life expectancy \> 12 weeks. * Women of child bearing potential must use effective contraception. * Men might be surgically sterile or accept to use an effective contraceptive procedure during and until 6 months after the treatment. * Written informed consent to participate in the study. Exclusion Criteria: * PS \> 2, exception : age \> 74 years only PS ≥ 2 * Presence of another cancer * Previous treatment with an anti egfr agent or docetaxel * QT prolongation (\>470 ms) * Uncontrolled arterial hypertension. * Concurrent radiotherapy, except for palliative bone irradiation. * Stroke less than 6 months before study entry. * Psychiatric or neurological disorders preventing the patient from understanding the nature of the trial * Uncontrolled infection. * Caval syndrome * Other organic disorders preventing inclusion in the trial * Malabsorption syndrome * Allergy to erlotinib or one of its constituents * Allergy to docetaxel or one of its constituents * Pregnancy and breast-feeding * Surgery less than two months before study entry